Health ❯ Healthcare ❯ Obesity

Treatment Options

Semaglutide Weight Loss Injections GLP-1 Medications GLP-1 Drugs GLP-1 Agonists Mounjaro Injectable Medications Tirzepatide Weight Loss Medications Oral Medications Pharmaceuticals Medication Efficacy Orforglipron Wegovy Medication Novo Nordisk Weight Loss Jabs Deprescription Strategies Weight Management Medications GLP-1 Receptor Agonists Injections Patient Access Bariatric Surgery Asthma Management Diet and Exercise Weight-Loss Injections NHS Availability Oral Therapies Injectable Drugs Medication Switching Clinical Pathways Medication Adherence NHS Access Inequality in Access Lifestyle Interventions Biological Factors FDA-Approved Medications Direct-to-Consumer Programs GLP-1 Therapies Amylin Analogs Medicare Coverage Semaglutide Approval Anti-Obesity Drugs Zepbound Chronic Disease Management Lifestyle Changes Hormonal Therapies Prescription Medications Mounjaro and Ozempic Zepbound (tirzepatide) Weight Loss Surgery Incretin-based Therapies Pills vs Injections Amycretin Surgical vs. Non-Surgical NHS Guidelines NHS Services Weight Loss Pills Injection Therapy Long-acting Medications Clinical Trials Surgical Interventions NHS Prescription NHS Prescribing

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

The once-weekly amylin analog also improved cardiometabolic markers with fewer side effects on slower dose escalation.

Lilly Taps Walmart for First Retail Pickup of Discounted Zepbound Vials Starting Mid-November

Sam’s Club Joins Costco in Offering $499 Wegovy and Ozempic

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects

Eli Lilly to Raise UK Mounjaro Prices by Up to 170% in September

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Bariatric Surgery Surpasses GLP-1 Drugs in Real-World Weight Loss